Trials / Completed
CompletedNCT01839968
Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 32 (actual)
- Sponsor
- University Hospital, Geneva · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this ex-vivo study is to estimate the optimal platelet quantity necessary to reverse the antiplatelet effects of prasugrel.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2013-12-01
- Completion
- 2014-01-01
- First posted
- 2013-04-25
- Last updated
- 2014-08-19
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT01839968. Inclusion in this directory is not an endorsement.